Fig 1.

EPO administration after myocardial infarction increased mobilization of EGFP⁺ BMCs from BM into peripheral blood in GFP-transgenic mice. (A) Representative FACS analyses of EGFP⁺ cells in bone marrow (left) and peripheral blood (right) of wild-type mice 10 weeks after BM-transplantation showing successful BM replacement. (B) Bar graph representing the percentage of EGFP⁺ cell populations (subclassified by CD31, c-kit, CXCR-4, Sca-1) in peripheral blood of infarcted control mice (white bar) or EPO-treated mice (black bar). All data represent mean ± S.E.M. (n = 8).